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Transcatheter aortic valve implantation (TAVI) has revo-
lutionized the treatment of symptomatic severe aortic ste-
nosis in patients at a high risk of surgical valve replacement
(1). The 2 main devices in clinical use at present are the self-
expandable Medtronic CoreValve (MCV) (Medtronic,
Minneapolis, Minnesota) and balloon-expandable Edwards
SAPIEN XT valve (ESV) (Edwards Lifesciences, Irvine,
California). Paravalvular aortic regurgitation (AR) is not an
uncommon complication after TAVI, and suboptimal device
sizing and positioning are the main culprits (2).See page 284Considering the reported association of AR after TAVI
with adverse outcomes and mortality (3,4), it is commend-
able that, in this issue of JACC: Cardiovascular Interventions,
Abdel-Wahab et al. (5) compared the occurrence of AR
after TAVI in patients treated with the MCV (n ¼ 276) and
the ESV (n ¼ 118). The principal ﬁnding is that AR,
assessed by either echocardiography or aortography, was
higher with the MCV than the ESV. However, the AR
index, which has also been shown to have prognostic value,
was similar for the 2 devices. Interestingly, although more-
than-mild AR was a predictor of 1-year mortality, there was
no difference in the 1-year survival rate based on the valve
types (MCV, 84% vs. ESV, 88%; p ¼ 0.42). The main
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ﬁndings are, therefore, prone to selection bias, and unmea-
sured confounders (e.g., operator preference, learning curve,
pattern of annular calciﬁcation) may not be corrected,
despite the authors’ attempt to perform propensity mat-
ching. This registry included patients from September
2007 to February 2012. However, the ESV has only been
available since May 2010, and the initial learning curve was
in the MCV group, for which only 26- and 29-mm valves
were available for most of the study duration. The occur-
rence of more-than-mild AR in patients treated with the
MCV appeared to decrease with operator experience (13%
before May 2010 and 9% after May 2010). When the
analysis was restricted to the time period in which both
devices were available (May 2010 to February 2012), the
incidence of more-than-mild AR was still higher with
the MCV than the ESV, but the magnitude of
difference was reduced. It appears that incidence of AR
decreases with operator’s experience; the recently reported
PRAGMATIC (Pooled-RotterdAm-Milano-Toulouse In
Collaboration) registry from 4 experienced European
centers has shown a substantially lower rate of more-than-
mild AR with both devices (2.0% with the MCV and 1.8%
with the ESV) (6).
Device-speciﬁc complications but no difference in clinical
outcomes. The higher incidence of AR after TAVI in
MCV-treated patients has also been reported in other
studies (7–9). Conversely, in the PRAGMATIC registry,
the incidence of AR was similar with both devices (6).
However, a meta-analysis of 45 studies (MCV, n ¼ 5,261
and ESV, n ¼ 7,279) has shown that moderate or severe
AR is more common with the use of the MCV (16% vs.
9%, p ¼ 0.005) (4). What remains important and somewhat
unexplained is that, despite the higher incidence of AR in
MCV-treated patients and the association of AR with
adverse outcomes, the patients treated with the MCV and
the ESV have been shown to have similar short- and long-
term outcomes. Two large and well-conducted registries,
UK-TAVI and FRANCE-2, have not shown any difference
in procedural success or mortality between patients treated
with the MCV and the ESV (7,8). A propensity-matched
study of 192 patients showed no difference in procedural
success, vascular complications, 30-day survival, and 1-year
survival (9). In the PRAGMATIC registry, 204 propensity-
matched patients had no difference in all-cause or cardio-
vascular mortality at 30-day or 1-year follow-up (6). It is
plausible that AR seen immediately after implantation of
the MCV continues to decline over time; data from a U.S.
pivotal trial (presented by Jeffrey Popma at Late Breaking
clinical trial session of the Transcatheter Cardiovascular
Therapeutics Conference, October 29, 2013, San Francisco,
California) showed that the proportion of patients with
more-than-mild AR decreased from 11.5% at 30 days to
4.1% at 1 year.
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294Imaging to guide selection and sizing of TAVI prosthesis. The
factors associated with occurrence of AR after TAVI include
the size of the aortic valve annulus, prosthesis undersizing,
and implantation depth and degree of annular calciﬁcation
(4,10,11). Several imaging, modalities, including aortog-
raphy, 2- or 3-dimensional echocardiography (transthoracic
or transesophageal), computed tomography (CT), and
magnetic resonance imaging, are available to assess annulus
size and calciﬁcation pre-procedure and AR post-procedure.
The valve sizing in the study of Abdel-Wahab et al. (5) was
based on 2-dimensional transthoracic echocardiography, and
CT was not routinely performed. There are data suggesting
that CT-derived aortic annular measurements offer more
appropriate valve sizing and are a better predictor of mod-
erate or severe AR after TAVI (10,12). It has been shown
that CT-based, compared with echocardiography-based,
annular sizing signiﬁcantly reduces AR after TAVI (12).
This study also highlighted that the incidence of reported
AR varies with the use of a different imaging modality.
More-than-mild AR seen on aortography (32.5% for the
MCV and 18.1% for the ESV) appears substantially higher
than that seen on echocardiography (12.7% for the MCV
and 2.6% for the ESV). Aortography is readily available
during the TAVI procedure to provide essential information
and guide further management; however, it is difﬁcult to
differentiate the contribution of central and paravalvular AR,
and interpretation can be very subjective.
Future directions: newer devices and personalized device
selection. Randomized studies to compare the efﬁcacy and
safety of various TAVI devices will be important after the
technology has matured sufﬁciently and indications are well
established. There are rapid technical and technological
advancements in the ﬁeld of TAVI, and both devices
compared in this study are likely to soon be “history.”
Medtronic and Edwards Lifesciences are developing newer-
generation valve systems to improve valve positioning and
reduce AR. The CoreValve Evolut-R has a retrievable/
repositionable system to facilitate precise positioning and an
extended skirt with modiﬁed cell geometry to reduce the
risk of AR. Edwards SAPIEN III incorporates a distal ﬂex
mechanism and ﬁne positioning control for accurate
placement and an additional cuff to reduce the risk of AR
(13). There are many other devices undergoing clinical
studies at the moment: Direct Flow Medical valve (Direct
Flow Medical Inc., Santa Rosa, California), JenaValve
(JenaValve, Munich, Germany), St. Jude’s Portico valve (St.
Jude Medical, St. Paul, Minnesota), and Symetis Acurate
(Symetis SA, Ecublens, Switzerland) have already received
the CE mark (13). It is likely that operators will have a
selection of devices to choose from in the near future.
Speciﬁc device-related factors may have an impact on
AR and other outcomes. Both devices have similar proce-
dural success, short- and long-term mortality, and risk of
major adverse cardiac events (6,7,9). However, patientswith greater annulus calciﬁcation, annulus eccentricity, and
aortic-left ventricle outﬂow tract angle are more predis-
posed to have AR after implantation of a self-expandable
MCV (14,15) and may be more suitable for treatment with
a balloon-expandable ESV. Conversely, a large annulus and
access site problems may dictate the use of an MCV
prosthesis. It would be desirable that centers performing
TAVI have access and expertise to use both devices.
Optimal pre-procedural imaging may help in selection of
the right size and type of device, and further randomized
data to compare the newer iterations of the 2 devices will
aid in recommending an individualized approach to device
selection.
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